UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 95

Sortiert nach

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

Clinical research in cardiology, 2023-11, Vol.112 (11), p.1639-1649

2023

Volltextzugriff (PDF)

PP027-MON THE ROLE OF LP(A) IN DIABETES MELLITUS AND INSULIN RESISTENCE – INVESTIGATION WITHIN THE BERLIN AGING STUDY BASE-II

Clinical nutrition (Edinburgh, Scotland), 2013-09, Vol.32, p.S133-S133

2013

Volltextzugriff (PDF)

A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis

International Journal of Rheumatology, 2012-01, Vol.2012, p.480784-10

2012

Volltextzugriff (PDF)

A lipidomic analysis approach in patients undergoing lipoprotein apheresis

Atherosclerosis, 2016-06, Vol.249, p.30-35

2016

Volltextzugriff (PDF)

Gene therapy: Case study on the first lipoprotein lipase deficiency patient treated with Alipogene Tiparvovec in Germany

Atherosclerosis, 2016-09, Vol.252, p.e83-e84

2016

Volltextzugriff (PDF)

Treatment of therapy-refractory hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9-I) in cardiovascular high risk patients – effectivity and safety in clinical routine

Atherosclerosis, 2016-09, Vol.252, p.e48-e48

2016

Volltextzugriff (PDF)

Case report: Hypercholesterolemic patient with new homozygous LDLR mutation and severe early coronary heart disease

Atherosclerosis, 2016-09, Vol.252, p.e31-e31

2016

Volltextzugriff (PDF)

Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study

Current medical research and opinion, 2006-02, Vol.22 (2), p.417-425

2006

Volltextzugriff (PDF)

Cerebrotendinous xanthomatosis – three patients, three faces

Atherosclerosis, 2021-08, Vol.331, p.e182-e183

2021

Volltextzugriff (PDF)

New data of the treatment with bempedoic acid in clinical routine

Atherosclerosis, 2022-08, Vol.355, p.224

2022

Volltextzugriff (PDF)

Lipid-lowering treatment of patients with statin intolerance – Interim analysis of an observational, prospective, multicenter registry

Atherosclerosis, 2023-08, Vol.379, p.S93

2023

Volltextzugriff (PDF)

Effects of nutritional intervention - Lessons from a kindred with familial hypobetalipoproteinemia

Atherosclerosis, 2023-08, Vol.379, p.S121

2023

Volltextzugriff (PDF)

Long-term lipid apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(A) elevation

Atherosclerosis, 2023-08, Vol.379, p.S16-S17

2023

Volltextzugriff (PDF)

Treatment With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (Pcsk9-I) In Clinical Routine – New Data Regarding Familial Hypercholesterolaemia (Fh) Genotype Safety And Efficacy

Atherosclerosis, 2019-08, Vol.287, p.e215-e216

2019

Volltextzugriff (PDF)

Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®)

International journal of clinical practice (Esher), 2007-11, Vol.61 (11), p.1914-1921

2007

Volltextzugriff (PDF)

High individual variability in LDL-reductions after inclisiran administration in a “real-world setting”

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

P1.32 A genetic variant within caveolin-3 protects against statin-induced myopathy

Neuromuscular disorders : NMD, 2010-10, Vol.20 (9), p.610-610

2010

Volltextzugriff (PDF)

Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice

Atherosclerosis, 2019-08, Vol.287, p.e212-e212

2019

Volltextzugriff (PDF)

Short Report Of A Longterm Outcome Of A Patient With Lysosomal Acid Lipase Deficiency And First Results After Initiation Of Treatment With Sebelipase Alfa

Atherosclerosis, 2019-08, Vol.287, p.e202-e202

2019

Volltextzugriff (PDF)

5001PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

PCSK9-Inhibitor treatment of cardiovascular high risk patients in clinical practice – New data regarding safety and effectivity

Atherosclerosis, 2018-08, Vol.275, p.e31-e31

2018

Volltextzugriff (PDF)

The German care high registry for familial hypercholesterolemia –Sex differences, treatment strategies, and target value attainment

Atherosclerosis, 2023-08, Vol.379, p.S124

2023

Volltextzugriff (PDF)

Clinical differentiation and mutation spectrum of chylomicronemia patients in a German outpatient clinic

Atherosclerosis, 2020-12, Vol.315, p.e43-e43

2020

Volltextzugriff (PDF)

Severe hypertriglyceridemia : Diagnostics and new treatment principles

Der Internist (Berlin), 2017-08, Vol.58 (8), p.866-876

2017

Volltextzugriff (PDF)

Lipoprotein(a): Epidemiologie und therapeutische Ansätze

Deutsche medizinische Wochenschrift, 2000-12, Vol.125 (44), p.1337-1343

2000

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Englisch
(78)
Deutsch
(17)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

PP027-MON THE ROLE OF LP(A) IN DIABETES MELLITUS AND INSULIN RESISTENCE – INVESTIGATION WITHIN THE BERLIN AGING STUDY BASE-II

A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis

A lipidomic analysis approach in patients undergoing lipoprotein apheresis

Gene therapy: Case study on the first lipoprotein lipase deficiency patient treated with Alipogene Tiparvovec in Germany

Treatment of therapy-refractory hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9-I) in cardiovascular high risk patients – effectivity and safety in clinical routine

Case report: Hypercholesterolemic patient with new homozygous LDLR mutation and severe early coronary heart disease

Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study

Cerebrotendinous xanthomatosis – three patients, three faces

New data of the treatment with bempedoic acid in clinical routine

Lipid-lowering treatment of patients with statin intolerance – Interim analysis of an observational, prospective, multicenter registry

Effects of nutritional intervention - Lessons from a kindred with familial hypobetalipoproteinemia

Long-term lipid apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(A) elevation

Treatment With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (Pcsk9-I) In Clinical Routine – New Data Regarding Familial Hypercholesterolaemia (Fh) Genotype Safety And Efficacy

Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®)

High individual variability in LDL-reductions after inclisiran administration in a “real-world setting”

P1.32 A genetic variant within caveolin-3 protects against statin-induced myopathy

Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice

Short Report Of A Longterm Outcome Of A Patient With Lysosomal Acid Lipase Deficiency And First Results After Initiation Of Treatment With Sebelipase Alfa

5001PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting

PCSK9-Inhibitor treatment of cardiovascular high risk patients in clinical practice – New data regarding safety and effectivity

The German care high registry for familial hypercholesterolemia –Sex differences, treatment strategies, and target value attainment

Clinical differentiation and mutation spectrum of chylomicronemia patients in a German outpatient clinic

Severe hypertriglyceridemia : Diagnostics and new treatment principles

Lipoprotein(a): Epidemiologie und therapeutische Ansätze

Suchergebnisse filtern